PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9298179-5	1997	Budesonide was added at concentrations corresponding to 10(-8), 10(-7), and 10(-6) mol/l in cultured epithelial cells, either in the absence of any stimulus or in the presence of interferon-gamma (IFN-gamma) at 500 U/ml.	Budesonide	0-10	interferon gamma	Homo sapiens	179-195	
9298179-5	1997	Budesonide was added at concentrations corresponding to 10(-8), 10(-7), and 10(-6) mol/l in cultured epithelial cells, either in the absence of any stimulus or in the presence of interferon-gamma (IFN-gamma) at 500 U/ml.	Budesonide	0-10	interferon gamma	Homo sapiens	197-206	
9298179-9	1997	In addition, budesonide reduced surface ICAM-1 upregulation induced by IFN-gamma at 500 U/ml (P < 0.05).	Budesonide	13-23	interferon gamma	Homo sapiens	71-80	
34414894-6	2021	Budesonide reduced synthesis of interleukin 4 (IL-4), CXCL8, tumor necrosis factor alpha (TNFalpha) by NK and NKT-like cells, as well as production of interferon gamma (IFNgamma) by NK cells.	Budesonide	0-10	interferon gamma	Homo sapiens	151-167	
8613948-6	1996	Budesonide (10(-7) M) dramatically reduced A-PBM proliferation (measured by 3H-thymidine incorporation) and cytokine (IL-1beta, IL-2, IL-6, IFN-gamma, TNF-alpha) production, but was not cytotoxic to immune cells.	Budesonide	0-10	interferon gamma	Homo sapiens	140-149	
7541423-6	1995	Pretreatment of cells with the glucocorticoid budesonide (10(-10)-10(-7) M) for 24 h inhibited expression of RANTES mRNA and protein stimulated by either TNF-alpha or TNF-alpha plus IFN-gamma in a concentration- and time-dependent manner.	Budesonide	46-56	interferon gamma	Homo sapiens	182-191	
34414894-9	2021	The combination of theophylline and budesonide suppressed synthesis of IL-4 and CXCL8 by NK and NKT-like cells, as well as the production of TNFalpha and IFNgamma by NK cells stronger than budesonide alone.	Budesonide	36-46	interferon gamma	Homo sapiens	154-162	
34414894-9	2021	The combination of theophylline and budesonide suppressed synthesis of IL-4 and CXCL8 by NK and NKT-like cells, as well as the production of TNFalpha and IFNgamma by NK cells stronger than budesonide alone.	Budesonide	189-199	interferon gamma	Homo sapiens	154-162	
34414894-6	2021	Budesonide reduced synthesis of interleukin 4 (IL-4), CXCL8, tumor necrosis factor alpha (TNFalpha) by NK and NKT-like cells, as well as production of interferon gamma (IFNgamma) by NK cells.	Budesonide	0-10	interferon gamma	Homo sapiens	169-177	
24717973-4	2014	Treatment of MSCs with glucocorticoids, budesonide or dexamethasone, enhanced IDO expression following IFN-gamma stimulation in multiple donors and was able to restore IDO expression in over-passaged MSCs.	Budesonide	40-50	interferon gamma	Homo sapiens	103-112	
35538539-8	2022	RESULTS: Our results show that both tanimilast and budesonide reduced the production of the immunostimulatory cytokine IFN-gamma by CD4+ T cells.	Budesonide	51-61	interferon gamma	Homo sapiens	119-128	
16160912-0	2005	The combined effects of zafirlukast, prednisone, and inhaled budesonide on IL-13 and IFN-gamma secretion.	Budesonide	61-71	interferon gamma	Homo sapiens	85-94	
10988100-7	2000	Budesonide decreased ex vivo generation of IL-5 and IFN-gamma by BAL cells.	Budesonide	0-10	interferon gamma	Homo sapiens	52-61	
22766315-4	2012	Moreover, we evaluated the potential effect of treatment with budesonide and/or formoterol on IFN-gamma secretion in vitro.	Budesonide	62-72	interferon gamma	Homo sapiens	94-103	
22766315-13	2012	Even if in vitro experiments with budesonide, alone or in combination with formoterol, showed a modulation of NKG2D receptor expression and IFN-gamma production, our ex vivo results show that real life LABA and ICS treatment does not influence peripheral NK cells count and their receptors phenotype.	Budesonide	34-44	interferon gamma	Homo sapiens	140-149